Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05367336 · ClinicalTrials.gov registry record · Phase 2

Platelet Reactivity With Fentanyl, Morphine, or no Narcotic

A Phase 2 study, sponsored by Corewell Health South.

Terminated
Registry status
Phase 2
Development phase
21
Enrollment target

NCT05367336 is a Phase 2 study that was terminated before completion, run by Corewell Health South. The registered enrollment target is 21 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05367336, a Phase 2 study, was terminated before completion, sponsored by Corewell Health South.

TERMINATED
Registry status
Phase 2
Development phase
21 participants
Enrollment target

Study Summary

The goal is to determine whether fentanyl and morphine have similar effects in reducing aspirin's effect upon platelets in emergency department patients with chest discomfort. Morphine has been shown to worsen outcomes in heart attack patients due to reduction of oral anti-platelet agent effectiveness and so many providers have switches to using fentanyl. However, it is largely unknown whether fentanyl has similar effects.

Interventions

  • DRUG Morphine
  • DRUG Fentanyl

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2022-08-31
Est. Completion 2025-02-18
Phase Phase 2

Sponsor

Corewell Health South

12 total trials

What the Registry Record Tells You About NCT05367336

The ClinicalTrials.gov registry entry for NCT05367336 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health South, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Morphine is the first listed.

NCT05367336 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05367336 about?

NCT05367336 is a clinical study titled "Platelet Reactivity With Fentanyl, Morphine, or no Narcotic". The goal is to determine whether fentanyl and morphine have similar effects in reducing aspirin's effect upon platelets in emergency department patients with chest discomfort. Morphine has been shown to worsen outcomes in heart attack patients due to reduction of oral anti-platelet agent effectivene...

What is the current status of trial NCT05367336?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2022-08-31. Estimated completion is 2025-02-18.

What interventions are being tested in trial NCT05367336?

The interventions under investigation include: Morphine (DRUG), Fentanyl (DRUG).

Who is sponsoring clinical trial NCT05367336?

This trial is sponsored by Corewell Health South, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.